Amiodarone in refractory life-threatening ventricular arrhythmias

Area of Science:

• Cardiology
• Pharmacology

Background:

• Life-threatening ventricular arrhythmias pose a significant clinical challenge.
• Conventional antiarrhythmic agents are often ineffective for refractory cases.

Purpose of the Study:

• To evaluate the efficacy and safety of amiodarone in patients with refractory ventricular arrhythmias.
• To assess amiodarone's impact on arrhythmia recurrence, mortality, and cardiac function.

Main Methods:

• A cohort of 96 patients with refractory ventricular arrhythmias received amiodarone treatment.
• Follow-up ranged from 6 to 40 months, with serial 24-hour Holter monitoring and electrophysiological studies.
• Clinical outcomes, including survival, recurrence, and side effects, were meticulously recorded.

Main Results:

• Amiodarone therapy resulted in a high survival rate (75% alive and well) among the treated patients.
• Significant reduction in ventricular tachycardia episodes and ectopic beats was observed on Holter monitoring.
• While electrophysiological study suppression was achieved in only 50%, clinical outcomes remained excellent.

Conclusions:

• Amiodarone is a highly effective prophylactic agent for recurrent, refractory life-threatening ventricular arrhythmias.
• The drug demonstrates a favorable safety profile, with no aggravation of heart failure observed.
• Amiodarone offers a valuable therapeutic option for patients unresponsive to conventional treatments.